Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis

NCT01963611 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01963611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01963611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis
Lead sponsor
EMD Serono
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2013
Completion date
March 31, 2015
Enrollment
255 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis